|
· L'USAMRIID
(United States Army Medical Research Institute of Infectious Diseases)
evaluated DNV3681 against Bacillus anthracis that triggers anthrax and
Francisella tularensis that triggers tularemia or rabbit fever, both bacteria
being classified in the "high priority" category of
biothreat agents
· DNV3681
demonstrated a superior in vitro efficacy compared to Ciprofloxacin which is
the product of reference when exposed to Bacillus anthracis
· These
data will be presented during ASM 2019 which will take place from the 20th to
the 24th of
June 2019 in San Francisco
· DNV3681 is
the active molecule of DNV3837, developed in parallel by DEINOVE as a
potential treatment for gastrointestinal infections caused by Clostridium
difficile
DEINOVE
(Euronext Growth Paris: ALDEI), a French biotech company that uses
a disruptive approach to develop innovative antibiotics and
bio-based active ingredients for cosmetics and nutrition, announces
that Maj. Steven Zumbrun, Ph.D. from the United States
Army Medical Research Institute of Infectious Diseases (USAMRIID) will
present, at the annual congress of the American Society of Microbiology,
results of the DNV3681 in vitro evaluation against Bacillus
anthracis and Francisella tularensis:
Bacillus
anthracis and Francisella tularensis are classified
as two of the most dangerous possible biological weapons. Such research could
lead to another application for DNV3681, the active molecule of DNV3837
currently being tested by DEINOVE as a treatment targeting Clostridium difficile,
the bacterium that causes gastrointestinal infections.
The standard
of care against Bacillus anthracis and Francisella
tularensis is currently Ciprofloxacin, a synthetic large spectrum
antibiotic from the fluoroquinolones' family. Several pathogenic
bacterial species have already developed a resistance against this family of
antibiotics and the long treatment needed for Post-exposure
Prophylaxis of Anthrax very often triggers a major intestinal
microbiota imbalance leading to likely Clostridioides difficile infections.
Therefore, there is an urgency to make efficient and validated alternatives
available.
The
fact that the DNV3681 is precisely very active against both Bacillus
anthracis and Clostridioides difficile makes
it an ideal candidate to fulfill that need.
|
No comments:
Post a Comment